On August 5, 2026, Neuland Laboratories Limited released its consolidated financial results for the quarter ending June 30, 2026, as per the exchange filings.
The company reported a total income of ₹650.07 crore and net profit of ₹147.67 crore for the quarter ended June 30, 2026.
For the quarter ended June 30, 2026, the total income reported by Neuland Laboratories reached ₹650.07 crore. This represents an 116.3% increase compared to the total income of ₹300.61 crore recorded in the same quarter of the previous year.
When evaluated on a quarter-on-quarter basis, the total income decreased by 17.6% from the ₹788.71 crore reported in the quarter ended March 31, 2026.
The net profit or Profit After Tax for the June 2026 quarter stood at ₹147.67 crore. This figure marks a 962.4% increase compared to the ₹13.90 crore profit recorded in the June 2025 quarter.
Compared to the preceding quarter ended March 31, 2026, where the net profit was ₹212.67 crore, the current figures represent a 30.6% decline.
The company also disclosed its financial performance for the full year of 2026. The total income for FY26 was recorded at ₹2,053.15 crore. Furthermore, the net profit or Profit After Tax for the entirety of FY26 was reported at ₹363.99 crore.
The company's Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) reached ₹231.1 crore, showing a year-on-year growth of 448.2% against ₹42.1 crore in the corresponding prior quarter.
The consolidated EBITDA margin expanded significantly by 2,150 basis points to settle at 35.5%. Sequentially, EBITDA fell 27.6% from ₹319.4 crore, resulting in a 500 basis point reduction in profitability margins.
The growth was supported by steady operations across the Custom Manufacturing Solutions (CMS) and Generic Drug Synthesis (GDS) segments.
Commercial products brought in the largest revenue chunk, while pipeline projects advanced into deeper, capability-led client interactions.
Management confirmed that ongoing capital expenditure projects are proceeding as scheduled, and investment intensity is expected to scale up further to capture emerging global contract development opportunities.
Read More: HT Media Share Price Gains Over 10% After Q1 FY27 Earnings Results: Total Income Up 14.8% YoY!
As of August 06, 2026, at 10:55 AM, Neuland Laboratories share price on NSE was trading at ₹21,551.00, up by 7.99% from the previous closing price.
Neuland Laboratories reported total income of ₹650.07 crore and net profit of ₹147.67 crore for the quarter ended June 30, 2026. For FY26, total income was ₹2,053.15 crore and net profit was ₹363.99 crore.
Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Aug 6, 2026, 12:28 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
